medigraphic.com
Medicina Universitaria

2008, Number 40

<< Back Next >>

Med Univer 2008; 10 (40)

First consensus of chronic lymphocytic leukemia of the Mexican Group for the Study of Hematology: epidemiology, diagnosis and treatment

Cano CR, Alvarado IM, Álvarez PE, Baltazar AS, Castellanos GJE, Castillo RMH, Díaz VG, Hernández PR, Hernández JM, Hernández JM, Ibarra GI, Kassack IJJ, Loarca PLM, Loera FS, Lomelí GA, López NH, May MEM, Montante JA, Murillo JE, Nacho VK, Ovilla MR, Pérez RO, Ruiz AGJ, Rozen FE, Silva MM, Silva LS, Zurita MH, Tarín ALC, Gómez AD

Language: Spanish
References: 40
Page: 159-167
PDF size: 410.72 Kb.


ABSTRACT

Chronic lymphocytic leukemia (CLL) is the less frequent chronic leukemia in Mexico. Considering recent advances in better prognostic classification and the introduction of new treatments, the Agrupación Mexicana para el Estudio de la Hematología organized the first Mexican consensus on CLL. The meeting was held in Cancun, México in September 2007. The aim of this meeting was to update and share the knowledge of the disease that Mexican specialists have, and improve diagnosis and treatment of CLL in our country. There is a need for registering these patients in a national database where samples are sent to. In this paper the clinical, therapeutic and diagnostic procedures of CLL are discussed.


REFERENCES

  1. Houlston RS, Catovsky D, Yuille MR. Genetic susceptibility to chronic lymphocytic leukemia. Leukemia 2002;16:1008-14.

  2. Aleman-Hoey D, Ruiz-Argüelles GJ, Verduzco-Rodríguez L, Lopez-Ariza B, Labardini JR. Leucemia linfocítica crónica. Experiencia de 35 años en el Instituto Nacional de la Nutrición Salvador Zubirán. Rev Invest Clin 1982;34:151-6.

  3. Ruiz-Argüelles GJ, Cantú-Rodríguez OG, Mercado-Díaz L, Apreza Molina y col. La frecuencia de algunas neoplasias linfoproliferativas crónicas es menor en México que en poblaciones caucásicas. Estudio Multicéntrico. Med Int Mex 1996;12:41.

  4. Ruiz-Argüelles GJ, Velázquez BM, Apreza-Molina MG, Pérez-Romano B y col. Chronic lymphocytic leukemia is infrequent in Mexican Mestizos. Int J Hematol 1999;69:253-5.

  5. Cabrera ME, Marinov N, Guerra C, Morilla R, Matutes E. Chronic lymphoproliferative syndromes in Chile. A prospective study in 132 patients. Rev Med Chil 2003;131:291-8.

  6. Mauro FR, Foa R, Giannarelli D, Cordone I, et al. Clinical characteristics and outcome of young chronic lymphocytic leukemia patients: a single institution study of 204 cases. Blood 1999;94:448-54.

  7. Ascani S, Leoni P, Fraternali Orcioni G, Bearzi I, et al. T-cell prolymphocytic leukemia: does the expression of CD8+ phenotype justify the identification of a new subtype? Description of two cases and review of the literature. Ann Oncol 1999;10:649-53.

  8. Tamura K, Sawada H, Izumi Y. Chronic lymphocytic leukemia (CLL) is rare, but the proportion of T-CLL is high in Japan. Eur J Haematol 2001;67:152-7.

  9. Catovsky D, Galetto J, Okos A, Galton DA, et al. Prolymphocytic leukemia of B and T cell type. Lancet 1973;2:232.

  10. Cheson BD, Bennett JM, Grever M, Kay N, et al. National Cancer Institute-sponsored working group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood 1996;87:4990-7.

  11. Montillo M, Hamblin T, Hallek M, Montserrat E, Morra E. Chronic lymphocytic leukemia: novel prognostic factors and their relevance for risk-adapted therapeutic strategies. Hematology 2005;90:391-9.

  12. Ravandi F, O’Brien S. Chronic lymphoid leukemias other than chronic lymphocytic leukemia: diagnosis and treatment. Mayo Clin Proc 2005;80:1660-74.

  13. Shanafelt TD, Byrd JC, Call TG, Zent CS, Kay NE. Narrative review: Initial management of newly diagnosed, early-stage chronic lymphocytic leukemia. Ann Intern Med 2006;145:435-47.

  14. Dighiero G, Travade P, Chevret S, Fenaux P, et al. B-Cell chronic lymphocytic leukemia: present status and future directions. Blood 1991;78:1901-14.

  15. Montserrat E. New prognostic markers in CLL. Hematology Am Soc Hematol Educ Program 2006;279-84.

  16. Binet JL, Auquier A, Dighiero G, Piquet H, et al. A new pronostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer 1981;48:198-206.

  17. Ruiz-Delgado GJ, Tarín-Arzaga LC. ZAP-70: un nuevo factor pronóstico en la leucemia linfocítica crónica. Med Int Méx 2006;22:32-5.

  18. D’Arena G, Tarnani M, Rumi C, Aydin S. Prognostic significance of combined analysis of ZAP-70 and CD38 in chronic lymphocytic leukemia, Am J Hematol 2007;82:787-91.

  19. Cymbalista F. Assessment of ZAP70 and other prognostic factors. Leuk Lymphoma 2007;48:S9.

  20. Sayala HA, Rawstron AC, Hillmen P. Minimal residual disease assessment in chronic lymphocytic leukaemia. Best Pract Res Clin Haematol 2007;20:499-512.

  21. Eichhorst B, Hallek M. Revision of the guidelines for diagnosis and therapy of chronic lymphocytic leukemia (CLL). Best Pract Res Clin Haematol 2007;20:469-77.

  22. Montserrat E, Sanchez-Bisono J, Vinolas N, Rozman C. Lymphocyte doubling time in chronic lymphocytic leukemia: Analysis of its prognostic significance. Br J Haematol 1986;62:567-75.

  23. Rai KR, Peterson BL, Appelbaum FR, Kolitz J, et al. Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. N Engl J Med 2000;343:1750-7.

  24. Catovsky D, Richards S, Matutes E, Oscier D, et al. UK National Cancer Research Institute (NCRI) Haematological Oncology Clinical Studies Group; NCRI Chronic Lymphocytic Leukaemia Working Group. Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial. Lancet 2007;370:230-9.

  25. Fabbri A, Lenoci M, Gozzetti A, Marotta G, et al. Low-dose oral fludarabine plus cyclophosphamide in elderly patients with chronic lymphoproliferative disorders. Hematol J 2004;5:472-4.

  26. Bezares RF, Caviglia D, Jaid C, Bar D, et al. Treatment of chronic lymphocytic leukemia with fludarabine (FAMP) oral plus cyclophosphamide (Cy). An interim analysis. Leuk Lymphoma 2007;48:S166.

  27. Keating MJ, O’Brien S, Maher A, Lerner S, et al. Early results of a chemo-immunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol 2005;23:4079-88.

  28. Wierda WG, O’Brien S, Wen S, Faderl S, et al. Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia. J Clin Oncol 2005;23:4070-8.

  29. Bezares RF, Stemmelin G, Argentieri D, Lanari E, et al. On behalf of the Latin American Cooperative Onco-Hematology Group (LACOHG). Subcutaneous alemtuzumab in patients with refractory/relapsed B-CLL after a fludarabine-based regimen. An interim analysis. Leuk Lymphoma 2007;48:S178.

  30. Dirección URL: . [Consulta: 8 de octubre de 2007].

  31. Wierda WG, O’Brien S, Thomas DA, Cortes J, et al. Combined cyclophosphamide, fludarabine, alemtuzumab and rituximab (CFAR) an active regimen for heavily treated patients with LLC. Blood 2006;108:S31.

  32. Osterbörg A. Alemtuzumab in CLL: current status and future prospects. Leuk Lymphoma 2007;48:S14.

  33. Milligan DW, Fernandes S, Dasgupta R, Davies FE, et al. National Cancer Research Institute Haemathological Study Group. Results of the MRC pilot study show autografting for younger patients with chronic lymphocytic leukemia is safe and achieves a high percentage of molecular responses. Blood 2005;105:397-404.

  34. Oscier D, Fegan C, Hillman P, ILLidge T, et al. Guidelines on the diagnosis and management of chronic lymphocytic leukemia. Br J Haematol 2004;125:294-317.

  35. Eichhorst BF. German CLL Study Group. CLL therapy in elderly patients: quality of life and outcome. Leuk Lymphoma 2007;48:S17.

  36. Dreger P. Stem cell transplants in CLL: When and How. Leuk Lymphoma 2007;48:S18.

  37. Gribben JG. Prognostic factors in patients with CLL who have received a stem cell transplant. Leuk Lymphoma 2007;48:S19.

  38. Sutton L, Chevret S, Nguyen F, Cazin B, et al. French Study Group on CLL and the Société Française de Greffe de Moelle et de Thérapie Cellulaire. Chemotherapy vs autotransplantation in CLL: the 2001 French trial. Leuk Lymphoma 2007;48:S21.

  39. Moreno C. MRD in CLL transplants: clinical significance and background for improving transplants. Leuk Lymphoma 2007;48:S22.

  40. Grever MR, Lucas DM, Johnson AJ, Byrd JC. Novel agents and strategies for treatment of p53-defective chronic lymphocytic leukemia. Best Pract Res Clin Haematol 2007;20:545-56.




2020     |     www.medigraphic.com